論文

筆頭著者
2021年3月

PD-L1 expression in tongue squamous cell carcinoma

Medical Molecular Morphology
  • Naoki Akisada
  • ,
  • Kohei Nishimoto
  • ,
  • Soshi Takao
  • ,
  • Yuka Gion
  • ,
  • Hidenori Marunaka
  • ,
  • Tomoyasu Tachibana
  • ,
  • Takuma Makino
  • ,
  • Kentaro Miki
  • ,
  • Yusuke Akagi
  • ,
  • Munechika Tsumura
  • ,
  • Tomohiro Toji
  • ,
  • Tadashi Yoshino
  • ,
  • Kazunori Nishizaki
  • ,
  • Yorihisa Orita
  • ,
  • Yasuharu Sato

54
1
開始ページ
52
終了ページ
59
記述言語
掲載種別
研究論文(学術雑誌)
DOI
10.1007/s00795-020-00261-7
出版者・発行元
Springer Science and Business Media LLC

Purpose: Immune checkpoint proteins programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are important therapeutic targets for head and neck cancer. This large-scale case study aimed to analyze tongue squamous cell carcinomas (SCCs) and evaluate the correlation between PD-L1 expression and clinical prognosis. So far, this study is the largest case study on PD-L1 expression in tongue SCCs.

Methods: This is a case-control study that analyzed 121 tongue SCCs. Paraffin-embedded sections and clinical data were obtained retrospectively and immunohistochemistry with PD-L1 was performed.

Results: 11.6% contained ≥ 50% of PD-L1-positive cells, 57.1% of these cases had a poor prognosis with nodal metastasis. Among cases of T1/2 primary lesions with nodal metastasis, cases of high PD-L1 expression had a significantly shorter disease-free survival than cases of no PD-L1 expression (p = 0.018). The hazard ratio for high PD-L1 expression was 3.21 (95 per cent CI, 1.26-8.72) compared with no PD-L1 expression after adjusting for other factors.

Conclusions: These data indicate that PD-L1 upregulation in tongue SCCs is associated with a more advanced stage and shorter disease-free survival. PD-1/PD-L1 inhibitors might hence constitute potential adjuvant therapy for tongue SCCs with PD-L1 upregulation.

Keywords: Adjuvant therapy; Nodal metastasis; Programmed cell death 1; Programmed cell death 1 ligand; Tongue squamous cell carcinoma.

リンク情報
DOI
https://doi.org/10.1007/s00795-020-00261-7
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32699939
URL
http://link.springer.com/content/pdf/10.1007/s00795-020-00261-7.pdf
URL
http://link.springer.com/article/10.1007/s00795-020-00261-7/fulltext.html
ID情報
  • DOI : 10.1007/s00795-020-00261-7
  • ISSN : 1860-1480
  • eISSN : 1860-1499
  • PubMed ID : 32699939

エクスポート
BibTeX RIS